Disease · MONDO_0005090
Comparisons in its trials317
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 317
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA | 43 of 4,905 | 65 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA | 17 of 4,905 | 8 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC | 31 of 4,905 | 12 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA | 13 of 4,905 | 21 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC | 68 of 4,905 | 76 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA | 34 of 4,905 | 32 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure | 3,136 of 4,905 | 2,597 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease | 174 of 4,905 | 149 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation | 10 of 4,905 | 6 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC | 19 of 4,905 | 28 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - ISC | 14 of 4,905 | 21 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| Sertindole vs Risperidone: serious adverse events | 266 of 4,905 | 217 of 4,904 | 9,809 | NCT00856583 | Trial comparisons |
| R092670 vs RISPERDAL CONSTA: serious adverse events | 41 of 606 | 29 of 608 | 1,214 | NCT00589914 | Trial comparisons |
| Paliperidone ER: Lack of Efficacy vs Paliperidone ER: Lack of Tolerability, Compliance or Other: serious adverse events | 35 of 512 | 29 of 587 | 1,099 | NCT01662648 | Trial comparisons |
| Conversion Phase vs Open-label Treatment Phase: serious adverse events | 2 of 297 | 49 of 510 | 807 | NCT01122927 | Trial comparisons |
Quetiapine XR vs Risperidone: The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Discontinued the Study Because of an TEAE at Month 12 in the Safety Population | 57 of 391 | 48 of 402 | 793 | NCT00600756 | Trial comparisons |
Quetiapine XR vs Risperidone: The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Extra-pyramidal TEAE at Month 12 in the Safety Population | 38 of 391 | 83 of 402 | 793 | NCT00600756 | Trial comparisons |
Quetiapine XR vs Risperidone: The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants With a Treatment-emergent Adverse Event (TEAEs) at Month 12 in the Safety Population | 238 of 391 | 258 of 402 | 793 | NCT00600756 | Trial comparisons |
Quetiapine XR vs Risperidone: The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Cardiac TEAE at Month 12 in the Safety Population | 22 of 391 | 17 of 402 | 793 | NCT00600756 | Trial comparisons |
| Quetiapine XR vs Risperidone: serious adverse events | 45 of 391 | 26 of 402 | 793 | NCT00600756 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005090/comparisons